Researchers develop gold nanoparticles to reduce neuronal cell death

NewsGuard 100/100 Score

Gold nanoparticles have been developed in the laboratory in order to reduce the cell death of neurons exposed to overexcitement.

The study is the result of an international collaboration coordinated by Roberto Fiammengo, a researcher at the Center of Biomolecular Nanotechnologies of the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) in Lecce (Italy).

The international team also involves colleagues at the University of Genoa, Imperial College London, King's College London, the Center for Synaptic Neuroscience and Technology of the Istituto Italiano di Tecnologia in Genoa and the Max Planck Institute for Medical Research in Heidelberg.

Excessive stimulation of neurons by the neurotransmitter glutamate, which is usually involved in the excitatory communication among neurons, can damage nerve cells and cause their degeneration.

This phenomenon, known with the term excitotoxicity, is common in many neuroinflammatory and neurodegenerative diseases, such as Alzheimer's and Huntington's disease, but also in case of epilepsy, brain trauma and stroke.

In particular, these nanoparticles were designed and prepared by the IIT team in Lecce (Italy), and are functionalized with peptides that allow selective inhibition of extrasynaptic glutamate receptors involved in the excitotoxicity.

In fact, the size of the nanoparticles is 20 - 50 times larger than that of classic drugs resulting in the blockade of only the receptors located outside the synapses. In this way, correct neurotransmission is preserved while the excessive activation that leads to cell death is avoided.

The molecular mechanism underlying the neuroprotective effect of the nanoparticles has been clarified by the experimental work carried out by Pierluigi Valente at the University of Genoa, in collaboration with Fabio Benfenati's group of the Center for Synaptic Neuroscience and Technology of the IIT in Genoa (Italy).

The results of this research set the basis for the treatment of neurological diseases in which the excessive release of glutamate is at the basis of the pathology.

The possibility of specifically blocking extrasynaptic receptors, mainly responsible for cell death, without interfering with synaptic transmission, opens up promising perspectives for targeted therapy without major side effects.

"We have developed nanoparticles with unique and necessary properties to answer to the indications of neurobiologists and physiologists - declares Roberto Fiammengo - Coordinating such a multidisciplinary group of researchers was an extremely stimulating task and the results obtained show that this is the winning approach."

Even if, at the moment, the nanoparticles developed cannot be used in therapy, this study shows how nanotechnology can provide important indications for treatment of many neuroinflammatory and neurodegenerative diseases."

Pierluigi Valente, Study First Author, University of Genoa

Source:
Journal reference:

Iakab, S. A., et al. (2020) Gold Nanoparticle-Assisted Black Silicon Substrates for Mass Spectrometry Imaging Applications. American Chemical Society Nano. doi.org/10.1021/acsnano.0c00201.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First-of-its-kind AI tool predicts patient response to cancer drugs at single-cell resolution